Amgen shares leapt in early trade after the company published second-quarter 2026 results that outperformed Wall Street forecasts on the major metrics and prompted a lift to full-year targets. In morning trading the stock climbed 6.2% to a new 52-week high of $416.22 as investors reacted to the quarterly beat and a more optimistic outlook.
For the quarter Amgen reported adjusted earnings of $6.29 per share and total revenue of $10.05 billion, a 10% increase year over year. Following the results the company raised its full-year 2026 revenue guidance to a range of $38.2 billion to $39.4 billion. Amgen also increased its adjusted EPS target to $22.30 to $23.50, up from the prior range of $21.70 to $23.10.
Management highlighted broad-based strength across product lines. In a company statement CEO Robert Bradway said, "Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales." That performance was a central rationale for the stronger full-year guidance.
Amgen disclosed it will stop development of AMG 513, an early obesity candidate that had been in Phase 1 testing. The company did not provide additional pipeline changes in the announcement beyond that program discontinuation.
The quarterly report spurred a wave of analyst target increases. BMO Capital raised its target to $450 from $400. Wells Fargo moved its target to $400 from $390. Canaccord increased its target to $384 from $366. RBC Capital raised its price target to $400 from $370 while retaining an Outperform rating following the quarter.
Market conditions supported the stock's move. Broad corporate earnings strength pushed stocks higher and the market extended gains into a fifth consecutive session, the longest rally for the S&P 500 since early June according to the market commentary accompanying today's session. The S&P 500 was up about 0.4% and the Dow Jones Industrial Average rose roughly 1.1% during the trading session, contributing to an environment that amplified investor enthusiasm for Amgen's results. Commentary also noted that nearly 90% of companies reporting results to date have beaten expectations.
Taken together, the decisive earnings beat, the guidance raise, the string of analyst price target increases and a constructive broad-market backdrop combined to drive an outsized move in Amgen shares. The stock reached an all-time high during the session, and the climb to $414.07 — reported intraday above its prior 52-week high — underscores how materially the Q2 disclosure shifted market sentiment toward a more optimistic view of Amgen's diversified product portfolio and renovated full-year targets.
Investors reacting to the quarter focused on the company's near-term cash flow profile reflected in the raised guidance and the share price momentum driven by upgraded broker targets. At the same time, the company’s pipeline decision on AMG 513 remains a discrete development investors will weigh alongside the top-line and earnings strength.
Key points
- Amgen beat Q2 expectations with adjusted EPS of $6.29 and revenue of $10.05 billion, a 10% year-over-year rise.
- The company raised full-year 2026 guidance to $38.2 billion - $39.4 billion in revenue and adjusted EPS to $22.30 - $23.50.
- Multiple brokerages increased price targets after the quarter; the broader market's strong earnings season aided the stock's advance.
Sectors impacted
- Biotechnology and healthcare equities, which respond to company fundamentals and pipeline news.
- Equity markets more broadly, given the contribution of a positive market backdrop to the share move.
Risks and uncertainties
- Pipeline change - Amgen announced it is discontinuing AMG 513, an early-stage obesity candidate previously in Phase 1. This represents a program-specific development investors will factor into pipeline valuation.
- Market sensitivity - The rally was supported by a constructive market environment and broad earnings strength; a reversal in market tone could reduce the upward pressure on Amgen shares.
- Analyst expectations - The share gains have been reinforced by several price-target increases; shifts in analyst outlooks or guidance adjustments in future quarters could alter sentiment.